NASDAQ
ANGO

AngioDynamics Inc

Medical Instruments & Supplies
Healthcare

Prices are adjusted according to historical splits.

AngioDynamics Inc Stock Price

Vitals

Today's Low:
$7.01
Today's High:
$7.22
Open Price:
$7.22
52W Low:
$11.35
52W High:
$24.87
Prev. Close:
$7.22
Volume:
741281

Company Statistics

Market Cap.:
$449.65 million
Book Value:
10.327
Revenue TTM:
$327.93 million
Operating Margin TTM:
-6.7%
Gross Profit TTM:
$164.93 million
Profit Margin:
-9.98%
Return on Assets TTM:
-2.47%
Return on Equity TTM:
-7.79%

Company Profile

AngioDynamics Inc had its IPO on 2004-05-27 under the ticker symbol ANGO.

The company operates in the Healthcare sector and Medical Instruments & Supplies industry. AngioDynamics Inc has a staff strength of 760 employees.

Stock update

Shares of AngioDynamics Inc opened at $7.22 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $7.01 - $7.22, and closed at $7.14.

This is a -1.11% slip from the previous day's closing price.

A total volume of 741,281 shares were traded at the close of the day’s session.

In the last one week, shares of AngioDynamics Inc have slipped by -7.63%.

AngioDynamics Inc's Key Ratios

AngioDynamics Inc has a market cap of $449.65 million, indicating a price to book ratio of 1.1873 and a price to sales ratio of 1.4776.

In the last 12-months AngioDynamics Inc’s revenue was $327.93 million with a gross profit of $164.93 million and an EBITDA of $8.60 million. The EBITDA ratio measures AngioDynamics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, AngioDynamics Inc’s operating margin was -6.7% while its return on assets stood at -2.47% with a return of equity of -7.79%.

In Q3.6666666666667, AngioDynamics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 9.1%.

AngioDynamics Inc’s PE and PEG Ratio

Forward PE
1111.1111
Trailing PE
0
PEG
1.87

Its diluted EPS in the last 12-months stands at $-0.78 per share while it has a forward price to earnings multiple of 1111.1111 and a PEG multiple of 1.87. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into AngioDynamics Inc’s profitability.

AngioDynamics Inc stock is trading at a EV to sales ratio of 1.6111 and a EV to EBITDA ratio of -120.9498. Its price to sales ratio in the trailing 12-months stood at 1.4776.

AngioDynamics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$558.21 million
Total Liabilities
$73.57 million
Operating Cash Flow
$-2496000.00
Capital Expenditure
$1.28 million
Dividend Payout Ratio
0%

AngioDynamics Inc ended 2024 with $558.21 million in total assets and $0 in total liabilities. Its intangible assets were valued at $558.21 million while shareholder equity stood at $407.96 million.

AngioDynamics Inc ended 2024 with $14.29 million in deferred long-term liabilities, $73.57 million in other current liabilities, 381000.00 in common stock, $-179903000.00 in retained earnings and $200.76 million in goodwill. Its cash balance stood at $29.86 million and cash and short-term investments were $29.86 million. The company’s total short-term debt was $0 while long-term debt stood at $49.80 million.

AngioDynamics Inc’s total current assets stands at $158.83 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $52.85 million compared to accounts payable of $34.69 million and inventory worth $63.18 million.

In 2024, AngioDynamics Inc's operating cash flow was $-2496000.00 while its capital expenditure stood at $1.28 million.

Comparatively, AngioDynamics Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$7.14
52-Week High
$24.87
52-Week Low
$11.35
Analyst Target Price
$24

AngioDynamics Inc stock is currently trading at $7.14 per share. It touched a 52-week high of $24.87 and a 52-week low of $24.87. Analysts tracking the stock have a 12-month average target price of $24.

Its 50-day moving average was $8.59 and 200-day moving average was $10.77 The short ratio stood at 4.43 indicating a short percent outstanding of 0%.

Around 502.7% of the company’s stock are held by insiders while 9621.3% are held by institutions.

Frequently Asked Questions About AngioDynamics Inc

The stock symbol (also called stock or share ticker) of AngioDynamics Inc is ANGO

The IPO of AngioDynamics Inc took place on 2004-05-27

Similar Industry Stocks (Medical Instruments & Supplies)

Last Price
Chg
Chg%
$6.75
-0.35
-4.93%
$656.45
-71.95
-9.88%
Exponent Inc (EXPO)
$89.32
0.72
+0.81%
$1166.05
-18.35
-1.55%
INCAP LTD. (INCAP)
$41
-1.49
-3.51%
$1471.45
-17.4
-1.17%
$5.48
0.27
+5.18%
$5052.45
-197.15
-3.76%
$18.15
0.35
+1.97%
$107.73
-1.23
-1.13%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon’s, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. In addition, the company provides endovascular therapies products in the areas of thrombus management, atherectomy, peripheral products (Core), and venous insufficiency. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies that are used primarily to deliver short-term drug therapies, such as chemotherapeutic agents and antibiotics, into the central venous system under the BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax names. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.

Address

14 Plaza Drive, Latham, NY, United States, 12110